ASTELLAS PHARMA EUROPE B.V.

Nanoform Q3 2024 report highlights record new non-GMP projects, revenue growth, and progress in GMP activities and product kernels. Key financials show revenue growth and increased gross profit, with ongoing manufacturing for pivotal studies and registration batches in Project Nanoenzalutamide. Dealmaking progress includes term sheets and LOIs, with expectations for license/commercial supply agreements. CEO's review emphasizes growth acceleration and strategic milestones achieved.